BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21658021)

  • 1. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.
    Yu Y; Suryo Rahmanto Y; Richardson DR
    Br J Pharmacol; 2012 Jan; 165(1):148-66. PubMed ID: 21658021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
    Quach P; Gutierrez E; Basha MT; Kalinowski DS; Sharpe PC; Lovejoy DB; Bernhardt PV; Jansson PJ; Richardson DR
    Mol Pharmacol; 2012 Jul; 82(1):105-14. PubMed ID: 22508546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.
    Whitnall M; Howard J; Ponka P; Richardson DR
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14901-6. PubMed ID: 17003122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
    Yuan J; Lovejoy DB; Richardson DR
    Blood; 2004 Sep; 104(5):1450-8. PubMed ID: 15150082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
    Yu Y; Suryo Rahmanto Y; Hawkins CL; Richardson DR
    Mol Pharmacol; 2011 Jun; 79(6):921-31. PubMed ID: 21389104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: structure-activity relationship studies on their anti-proliferative and iron chelation efficacy.
    Lukmantara AY; Kalinowski DS; Kumar N; Richardson DR
    J Inorg Biochem; 2014 Dec; 141():43-54. PubMed ID: 25217717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.
    Krishan S; Richardson DR; Sahni S
    Biochim Biophys Acta; 2016 Dec; 1863(12):2916-2933. PubMed ID: 27639899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
    Lovejoy DB; Sharp DM; Seebacher N; Obeidy P; Prichard T; Stefani C; Basha MT; Sharpe PC; Jansson PJ; Kalinowski DS; Bernhardt PV; Richardson DR
    J Med Chem; 2012 Aug; 55(16):7230-44. PubMed ID: 22861499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21
    Moussa RS; Kovacevic Z; Bae DH; Lane DJR; Richardson DR
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):761-774. PubMed ID: 29032246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity.
    Kovacevic Z; Kalinowski DS; Lovejoy DB; Quach P; Wong J; Richardson DR
    Curr Drug Deliv; 2010 Jul; 7(3):194-207. PubMed ID: 20507267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.
    Lee JC; Chiang KC; Feng TH; Chen YJ; Chuang ST; Tsui KH; Chung LC; Juang HH
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.
    Debebe Z; Ammosova T; Breuer D; Lovejoy DB; Kalinowski DS; Kumar K; Jerebtsova M; Ray P; Kashanchi F; Gordeuk VR; Richardson DR; Nekhai S
    Mol Pharmacol; 2011 Jan; 79(1):185-96. PubMed ID: 20956357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.
    Stefani C; Jansson PJ; Gutierrez E; Bernhardt PV; Richardson DR; Kalinowski DS
    J Med Chem; 2013 Jan; 56(1):357-70. PubMed ID: 23276209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
    Kalinowski DS; Yu Y; Sharpe PC; Islam M; Liao YT; Lovejoy DB; Kumar N; Bernhardt PV; Richardson DR
    J Med Chem; 2007 Jul; 50(15):3716-29. PubMed ID: 17602603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy.
    Lukmantara AY; Kalinowski DS; Kumar N; Richardson DR
    Bioorg Med Chem Lett; 2013 Feb; 23(4):967-74. PubMed ID: 23312948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
    Potuckova E; Jansova H; Machacek M; Vavrova A; Haskova P; Tichotova L; Richardson V; Kalinowski DS; Richardson DR; Simunek T
    PLoS One; 2014; 9(2):e88754. PubMed ID: 24586383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Halogenated 2'-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity.
    Stefani C; Punnia-Moorthy G; Lovejoy DB; Jansson PJ; Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2011 Oct; 54(19):6936-48. PubMed ID: 21846118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
    Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
    Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
    Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity.
    Lukmantara AY; Kalinowski DS; Kumar N; Richardson DR
    Org Biomol Chem; 2013 Oct; 11(37):6414-25. PubMed ID: 23963445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.